Immunohistochemistry Market

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period. Factors such as the growing geriatric population, rising prevalence of cancer, technological advancements in immunohistochemistry (IHC) technology, reimbursement policies for immunohistochemistry (IHC) tests, and the adoption of digital pathology are driving the growth of the immunohistochemistry (IHC) market. However, the high degree of consolidation is expected to restrain the market’s growth during the forecast period. A lack of standardization is a major challenge to the growth of this market.

The global immunohistochemistry market is highly competitive. Prominent players operating in the global immunohistochemistry market include F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product launches and approvals to expand their product and geographic footprint and increase market presence.

To know about the assumptions considered for the study download the pdf brochure

F. Hoffmann-La Roche AG (Switzerland)

Hoffmann-La Roche AG (Switzerland) is a biotechnology company focusing on the development and manufacturing of pharmaceutical and diagnostic products. Within the immunohistochemistry (IHC) market, Roche operates through its Pathology Lab segment, part of the Diagnostics Division. The company offers a wide range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit (OptiView). Roche has strengthened its position as a key market player through product launches, including both new and improved products with expanded application bases. Roche has added several products to its portfolio, such as the BenchMark ULTRA PLUS system launched in June 2022, VENTANA DP 600 slide scanner launched in June 2022, Elecsys anti-p53 Immunoassay launched in April 2021, and VENTANA ALK (D5F3) CDx Assay launched in March 2021 to strengthen its IHC offerings. Additionally, the company has received product approvals for new primary antibodies and the VENTANA MMR RDx systems for various disease applications. Roche maintains a global presence across Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.

Danaher Corporation (US) is a science and technology company specializing in the design, manufacture, and distribution of medical, industrial, and commercial products and services. Through its subsidiary Leica Biosystems, under the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments, Danaher offers various chemical and immuno-staining instruments, reagents, and consumables. Key factors contributing to the company's market leadership include its wide customer base, use of advanced technology-enabled solutions, substantial investment in research and development (R&D), and comprehensive quality product lines. For instance, in 2023 the company invested USD 1.50 billion in research and development.

These R&D investments support the development of new products and improve the existing ones' functionality, effectiveness, ease of use, and reliability. The company also collaborates with research institutions, universities, and clinicians worldwide to develop better technologies and products. For instance, in June 2024, Leica Biosystem Nussloch GmbH, a subsidiary of Danaher Corporation partnered with Navinci (Sweden) to advance cancer research using automated in situ proximity ligation assays on the BOND RX Fully Automated Research Stainer. Additionally, in November 2022, Leica Biosystems Nussloch GmbH acquired Cell IDx, Inc., an immunodiagnostic company specializing in chromogenic and fluorescent multiplex IHC biomarker profiling products. These developments strengthen Danaher's competitive position in the IHC market.

Agilent Technologies, Inc. (US) is a major player in the life sciences, diagnostics, and applied chemical markets, providing application-focused solutions including instruments, software, services, and consumables for laboratory workflows in food, environmental, forensics, pharmaceutical, diagnostic, chemical & energy, and research fields. Agilent operates in the IHC market through Pathology Solutions, part of its Diagnostics and Genomics segment, offering IHC products for cancer diagnostics and anatomic pathology workflows.

In January 2024, Agilent partnered with Incyte (US) to develop companion diagnostic solutions for oncology and hematology, expanding its portfolio with novel biomarkers. Similarly, in January 2023, Agilent collaborated with Akoya Biosciences to develop chromogenic and immunofluorescent multiplex assays for immunohistochemistry diagnostic solutions. Agilent is also expanding in both developed and developing regions. In 2022, the company established a Center for Excellence (CoE) in India to innovate new products for analytical chemistry, biopharmaceuticals, and life science research. Agilent has a global presence, including in the US, UK, Australia, China, Germany, Italy, Malaysia, Singapore, Belgium, Denmark, Japan, and the Netherlands.

Related Reports:

Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]